摘要
Prostate cancer （PC） is the second most diagnosed visceral malignancy in men worldwide, with over 900 000 new diagnoses each year.1 Approximately 50% of patients treated in industrialized nations will receive androgen deprivation therapy （ADT） at some point in their lifetimes.2 The use of ADT as a treatment approach is likely to increase as new drug developments have focused on intensifying the effect of reducing androgen receptor activation.
Prostate cancer （PC） is the second most diagnosed visceral malignancy in men worldwide, with over 900 000 new diagnoses each year.1 Approximately 50% of patients treated in industrialized nations will receive androgen deprivation therapy （ADT） at some point in their lifetimes.2 The use of ADT as a treatment approach is likely to increase as new drug developments have focused on intensifying the effect of reducing androgen receptor activation.
